Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company’s…
VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal…
PFÄFFIKON, Switzerland–(BUSINESS WIRE)–Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr.…
MALMÖ, Sweden & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Trialbee, a world-leading technology provider in patient matching and engagement, is partnering with…
Checkmate Pharmaceuticals has added experienced industry executives to lead clinical research and regulatory affairs with the appointments of James Wooldridge,…
Takeda said Tuesday it will sell certain OTC and non-core assets for over $200 million to ACino, to accelerate deleveraging as it said it will simplify portfolio in Takeda’s NEMEA region.
SAN DIEGO–(BUSINESS WIRE)–BioMed Realty, a leading provider of real estate solutions for the life science industry, announced today that it…
Allergan’s shareholders have voted to approve to be bought by AbbVie Inc for approximately $63 billion, as more than 99 percent of the votes cast were in favor of the transaction, representing about 69% of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland.
The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.
Lineage Cell Therapeutic has presented results of testing OpRegen, which continues to be well tolerated with increased visual acuity observed…